Huge effect of mTOR inhibition (sirolimus, everolimus?) in tuberous sclerosis academic.oup.com/ckj/article/... in @[email protected] Not an RCT of course - rare disease and all that! Via @[email protected] on LI #NephSky

Real-world management of tuber...

save the date the 2027 #ISNWCN @[email protected] will be in Kuala Lumpur #NephSky

I clearly missed the memo! RIP DI AVP-R (nephrogenic DI) AVP-D (central DI) www.cmaj.ca/content/198/... #NephSky #EndoSky

In this edition, @[email protected] breaks down the Bayesian voodoo behind removing evil humor www.nephjc.com/news/2026/sh... #EMIMCC #NephSky

NephJC Short: Bayesian leash:...

Are you still interested in contrast and AKI? @[email protected] and @[email protected] invited me to pontificate Watch it here youtu.be/ZhJTKnm8iZg #NephSky

CM-induced AKI: Myth or Realit...

RIP Lise Bankir - kidney stones physiologist extraordinaire www.kidney-international.org/article/S008... in @kidneyint.sky.social #NephSky

kidney-international.org/article/S0085-...

recording the latest edition of @[email protected] with Harish Seethapathy and Ewout Hoorn #NephSky (Not by planning but last minute cancellations lead to this manel)

#openaccess review on HDF and MCO in @[email protected] www.ajkd.org/article/S027... The interesting thing is they don’t even consider what the will say if H4RT comes back negative? (Enrolment and follow up completed - results expected in a few more months) #NephSky

Beyond Diffusion: Clinical Per...